On June 22, 2025, Ocugen, Inc. entered into a merger agreement with OrthoCellix, where OrthoCellix will merge into a subsidiary of Carisma Therapeutics, resulting in Ocugen owning about 90% of the combined company after a $25 million investment. The merger is subject to various conditions including stockholder approvals and regulatory requirements.